Abstract
Although our findings did not reveal a definitive antibody signature for severe disease, the
previously proposed biomarker of αvβ3-specific antibodies has been questioned and falsified.
Other features such as glycosylation and functional properties have been emerged as more
relevant predictors. Given the complexity of the immune response, it is unlikely that a single
biomarker will be predictive but rather a panel of markers is needed. We support the initiation
of a screening program based on current knowledge which can be refined over time as more
data becomes available.
| Original language | English |
|---|---|
| Qualification | Doctor of Philosophy |
| Awarding Institution |
|
| Supervisors/Advisors |
|
| Award date | 17 Mar 2026 |
| Place of Publication | Utrecht |
| Publisher | |
| Print ISBNs | 978-94-6522-684-2 |
| DOIs | |
| Publication status | Published - 17 Mar 2026 |
Keywords
- FNAIT
- integrins
- platelets
- HPA-1a